Veterinary drug for the treatment of viral diseases in carnivores "diverted"

 

(57) Abstract:

Usage: veterinary medicine. The inventive Preparation contains as the active component of 5.0 to 5.8% of the total mass, morpholine 3-methyl-1,2,4-triazolyl-5-thioacetate, and as a binder basics 14,0-16,0% emulsifier in the mixture with the complement to 100% of the mass of the preparation of the sunflower oil hydrogenation product. The medication comes in the form of candles weighing 1.5 g, rectally administered to the animals -12 candles for the full course of treatment.

The invention relates to veterinary medicine and can be used in the production of veterinary preparations for the treatment of viral diseases, in particular for the treatment of enteritis, hepatitis and distemper in carnivores (dogs, muskrats, foxes, etc).

Known by and. C. N 1834663, class A 61 K 27/00 method of treatment of viral diseases by introducing into the body an immunomodulating drug, which drug use dunatoi RNA with the wrong binding.

This drug is effective for treating a variety of viral diseases, but is ineffective for the treatment of enteritis and hepatitis in carnivores and are not effective for large viruses, such as viruses distemper.

You know the animal passes, every 8 to 12 hours, to recover.

This tool is quite effective in the treatment of enteritis bacterial etiology, but almost no positive action in the treatment of distemper in carnivores.

Known by and.with. N 1819615, class 5 A 61 K 31/19 way to prevent parasitic enteritis of pigs when pigs enter antioxidant drug tinosan, which ask the animals a single dose of 10 to 25 mg/kg weight of the animal.

This drug is an effective tool for the prevention of enteritis in piglets and is applicable to other animals, but has no effect in the treatment of already infected animals, and especially in the treatment of distemper in carnivores.

Known drug and.with. N 1794551, class 5 A 61 K 31/00, containing as the active component buzelin, streptocid, trypsin, methionine, turpentine, ASD-faction-2, revitalin HELL, hydrolysis, glucose, glycerol and water as a binder basics.

This medication is used to treat respiratory diseases, but it is effective in the treatment of other diseases of viral origin, but also as others mentioned analogues are not active against major virus distemper and ineffective in the treatment of

The purpose of the invention increase the efficiency of the veterinary drug for the treatment of viral diseases in carnivores, providing effective impact both small and large viruses, in particular enteritis, hepatitis and distemper.

Achieving this goal provides veterinary drug "Diverted" for the treatment of viral diseases in carnivores, including an active component and a binder basis due to the fact that as the active component used morpholine 3-methyl-1,2,4-triazolyl-5-thioacetate showing hepatoprotective, wound healing and antiviral activity, and as a cohesive framework used a mixture of hydrogenated feed is cut sunflower oil with emulsifier T-1 in the following ratio, wt. morpholine 3-mactel-1,2,4-triazolyl 5-thioacetate 5,0 5,8; emulsifier T-1-14,0-16,0; hydrogen ZAT sunflower oil the rest.

The invention is illustrated below by the description. The active component of the veterinary drug according to the invention is a substance that promotes rapid resolution of the disease morpholine 3-methyl-1,2,4-triazolyl-5-thioacetate showing hepatoprotective, wound healing and antiviral activity.

the invention of this powder is finely ground in a ball mill.

The common basis is the hydrogenation product of sunflower oil that softens the walls of the rectal tract of the animal and promoting the best difundieran through them in the blood of the active component.

The preparation according to the invention is introduced animals rectal. However, the hydrogenation product of sunflower oil liquid, making it difficult rectal administration of the drug to animals.

Clinical studies of this drug in liquid form, administered by injection, showed significantly worse results in comparison with rectal administration.

Accordingly, in the hydrogenation product of sunflower oil type emulsifier T-1, contributing to the solidification of the mixture and the formation of her candles drug.

The mixture is hydrogenated feed is cut sunflower oil with emulsifier T-1 receive by heating them to a temperature of 552oC and thorough mixing while maintaining this temperature.

In a heated and thoroughly mixed the mixture gradually parts add ground substance active component of morpholine 3-methyl-1,2,4-triazolyl-5-thioacetal, continuing the agitation while maintaining the temperature 552oC until a homogeneous molten mass of the drug.

ganizat sunflower oil to 100% of the total weight of the preparation.

To obtain a batch of 10,000 candles 1.5 g take: morpholine 3-methyl-1,2,4-triazolyl-5-thioacetate-1,03 kg, emulsifier T-1, 2.6 kg, hydrogenated feed is cut sunflower oil 15,5 kg

This ratio corresponds to the average value of the above intervals. When using the extreme lower limit of the active component of the treatment effect is reduced to a minimum. When using the upper limit of the active component of the effect of treatment is not increased, as it reached 100% on average, and the cost of the drug is greatly increased.

When using the lower extreme of the emulsifier T-1 candles do not get the required hardness, which makes their storage and the introduction of animals.

When using the extreme upper limit of emulsifier T-1, the candles out too hard, which slows melting in the body of the animal.

The molten mass of the obtained preparation is poured into the mold, put in the fridge and cool for 15 to 20 minutes at a temperature of 6oC.

After cooling, the candles are removed from the nests of the mold, obvolakivajut one candle in Matt paper and 12 candles Packed in carton.

Valitov and distemper according to the scheme: 1 2 one candle 4 times a day, 3 4 day one candle 2 times a day. Throughout the course of treatment, 12 candles on 1.5 g each.

In clinical testing were used 3 dogs, patients with enteritis and 2 dogs suffering from distemper.

All dogs in the use of candles drug recovered. In the second clinical validation were used 4 dogs suffering from enteritis, 4 dogs suffering from distemper, 2 dogs, hepatitis patients, all dogs also recovered when using candles drug under the above scheme.

It was thus established that the veterinary drug "Diverted" for the treatment of viral diseases is effective for enteritis, distemper and hepatitis.

According to the results of blood tests and other factors established that the drug exerts an immunomodulatory effect on the reaction of cellular and humoral immunity, increasing the synthesis of plasma cells antibodies, increasing the proliferative activity of T and B-lymphocytes, raises the number of lymphocytes to the level of healthy animals. Increases the nonspecific resistance of the organism, increasing the phagocytic activity of mononuclear, the level of lysozyme and leukocytes in the blood. Possesses hepatoprotective effect and normalizes the function is side effects during treatment.

Veterinary drug for the treatment of viral diseases in carnivores, including an active component and a connecting base, wherein as the active component contains morpholine-3-methyl-1,2,4-triazolyl-5-thioacetate, and as a cohesive framework contains a mixture of vegetable oil with hardener in the following ratio, wt.

Morpholine-3-methyl-1,2,4-triazolyl-5-thioacetate 5,0 5,8

Hardener 14,0 16,0

Vegetable fat Ostalnoe

 

Same patents:

The invention relates to medicine, namely to the production of medicines on the basis of [N-methyl-N/D-glyukopiranozil/ammonium-2-/acridin-9-one - 10-Il/acetate]-cycloferon, and can be used for the treatment of neoplastic diseases

The invention relates to antimicrobial compound used as a drug for humans and animals, and fish

The invention relates to new biologically active chemical compounds, namely, to derive a cyclic amide of the formula I

R1-(CH2)n-Z,

where R1group cyclic amide, such as 2H-3,4-dihydro-1,3-benzoxazin-2-she, 2H-3,4-dihydro-1,3-benzoxazin-2,4-dione, and 1,2,3,4-tetrahydroquinazoline-2,4-dione, and 1,2,3,4-tetrahydroquinazolin-2-it, 1,2,3,4-tetrahydropyrido(3,2-d)-pyrimidine-2,4 - dione, and 1,2,3,4-tetrahydropyrido(3,2-d)pyrimidine-2-it, 1,2,3,4-tetrahydropyrimidine-2,4-dione, pyrrolidin-2-it, 1,2,3,4 - tetrahydropyridine-2-it, 5H-6,7,8,9-tetrahydropyrido(3,2-b)azepin-6-she N-5,6,7,8-tetrahydropyrido(2,3-b)azepin - 8-she, 2H-3,4-dihydropyrido(2,3-e)-1, 3-oxazin-2-thione or 2-she pyrrolidine (3,4-b)-pyrazin-5-she 1H-2,3,4,5-tetrahydrothieno(2,3-b)indol-2-it, 8H-4,5,6,7-tetrahydrothieno(2,3-b)thiophene-7-she 4H-pyrazolo(5,4-f)benzazepin-9-it, isoindoline-1,3-dione, benzoxazolyl-2-it, unsubstituted or substituted lower alkyl, lower alkoxy, halogen, the nitro-group, carboxy, benzoyl or benzyl, n is zero or an integer from 1 to 6, Z is a group of formula (A) or (B):

N-(CH2)mR2(A) or -(CH2)p, dioxolane, furan, tetrahydrofuran, methylfuran or thiophene, m is an integer from 1 to 3; R3is lower alkyl; R4is phenyl or a radical of dioxolane, furan or thiophene, p = 1, provided that when R1radical 1,2,3,4-tetrahydrobenzo-2-or 1,2,3,4-tetrahydroquinazoline-2,4-dione, R2and R4are not phenyl or substituted by a halogen phenyl, or their pharmacologically acceptable salts with antiacetylcholinesterase activity
The invention relates to medicine, more specifically to means "Chloris" for the treatment of rhinitis

The invention relates to medicine, namely to medicines, and can be used in surgery for the treatment of purulent wounds

The invention relates to new, therapeutically valuable derivative tetrazole, method of their production and their use

The invention relates to veterinary medicine, in particular to methods for treating visceral mycosis rabbits, caused by a pathogenic fungus of the genus Aspergillus fumigatus

The invention relates to the field of medicines, in particular to the creation of drugs used in medicine and veterinary medicine for the treatment and prevention of diseases and conditions involving intoxication, vomiting, diarrhea, such as gastrointestinal diseases, food poisoning, septic conditions

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, endocrinology, pharmacology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical combined composition used for treatment or prophylaxis of hypertension in patients suffering with diabetes mellitus. The composition comprises AT1-antagonist valsartan or its pharmaceutically acceptable salt and calcium channel blocking agent or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier. The composition elicits synergistic effect and expanded spectrum effect.

EFFECT: improved and valuable medicinal properties of composition.

10 cl, 3 tbl

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to new derivatives of benzimidazole represented by the following formula (I) or its salt:

wherein R1 represents (lower)-alkyl group; R2 represents aromatic (lower)-alkyl group that can be substituted with one or more groups taken among halogen atom, alkyl group, halogen-(lower)-alkyl group, nitro-group, aromatic group, aromatic (lower)-alkoxy-group, (lower)-cycloalkyloxy-(lower)-alkyl group, aromatic (lower)-alkyl group, aromatic (lower)-alkenyl group, aromatic (lower)-alkynyl group, aromatic oxy-(lower)-alkyl group, (lower)-cycloalkyl-(lower)-alkoxy-group, alkenyl group, (lower)-alkoxy-group, (lower)-alkylthio-group and (lower)-alkanesulfonylcarbamoyl group; R3 represents alkyl group, hydroxy-(lower)-alkyl group, alkenyl group, aromatic group, halogenated aromatic group, (lower)-alkyl aromatic group, (lower)-alkenyl aromatic group or aromatic (lower)-alkenyl group; -X- represents cross-linking group represented by one of the following formulas: (II) , (III) , (IV) , (V) . Also, invention relates to pharmaceutical compositions eliciting activity that reduces blood glucose level based on this compound. Invention provides preparing new compounds and pharmaceutical compositions based on thereof used for prophylaxis and treatment of damaged tolerance to glucose, diabetes mellitus, insulin-resistance syndrome, vascular failures syndrome, hyperlipidemia and cardiovascular disorders.

EFFECT: valuable medicinal properties of compounds and compositions.

16 cl, 1 tbl, 86 ex

FIELD: medicine, pharmacology, pharmacy.

SUBSTANCE: invention proposes the composition comprising xenon as NMDA-antagonist and alpha-2-adrenergic agonist used for treatment of tetanus or narcotics (alcohol) withdrawal syndrome, states with chronic pain syndrome. Also, invention relates to the anesthetic composition comprising xenon and alpha-2-adrenergic agonist and to a method for anesthesia. The synergistic interaction of xenon as NMDA-antagonist and alpha-2-adrenergic agonist provides reducing the dose and to maintain the prolonged effectiveness by prevention for arising the drug habitation to the claimed preparation.

EFFECT: valuable medicinal properties of composition.

9 cl, 6 dwg, 6 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with mixing water for injections, conservation agent, metronidasol till complete dissolving at 50-60 C, adding a buffer (NaOH solution) pH 4.5-6.5 at pre-estimated quantity of water, then one should sterilize the obtained medicinal form due to membranous filtration followed by sterile packaging. As a conservation agent one should apply sodium chloride at the quantity of 1.5-2.0 against metronidasol weight, then metronidasol solution should be supplemented with a half-volume of sodium chloride solution, after complete dissolving the obtained solution should be supplemented with the rest quantity of sodium chloride solution. As for membranous filtration it should be carried out by applying a capsule out of polypropylene with hydrophilic membrane of 1.2 mcm. The method provides no crystallization of an active substance during prolonged period of time.

EFFECT: higher therapeutic efficiency.

1 ex, 1 tbl

Up!